Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

(2009) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

(2009) N. S. Azad et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

(2008) D Strumberg et al.   BRITISH JOURNAL OF CANCER

VEGF inhibition: insights from preclinical and clinical studies

(2008) Yongping Crawford et al.   CELL AND TISSUE RESEARCH

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy

(2008) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE